Remote Jobs at Madrigal Pharmaceuticals
Madrigal Pharmaceuticals
51 - 200 employees
💊 Pharmaceuticals
🧬 Biotechnology
⚕️ Healthcare Insurance
💰 $259M Post-IPO Equity on 2022-12
Pharmaceuticals • Biotechnology • Healthcare Insurance
Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing novel therapeutics for nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis (MASH). The company achieved a significant milestone with the accelerated FDA approval of its first therapy for adults with NASH with moderate to advanced liver fibrosis. Madrigal is actively conducting a Phase 3 trial for the treatment of NASH with compensated cirrhosis. The company is dedicated to improving care for patients with NASH/MASH through its ambitious research programs and therapeutic developments.
Is on LinkedIn?
